en · de · es · pt
melanotan-2-notes.peptides1004.com › Data › Background And Chemical Profile — What the Evidence Shows

Background And Chemical Profile — What the Evidence Shows

By Editorial Desk · published 2026-05-30 · last reviewed 2026-07-21 · Data

The short version of melanocortin fits in a sentence. The long version — which is the one that helps — is below.

This page was last updated on 2026-07-21 and is reviewed periodically as new material appears.

Background and Chemical Profile

Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.

Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.

Chemical Background and Receptor Activity

The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.

Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.

Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.

Melanotan-2 at a glance

PropertyValueNotes
Molecular classSynthetic cyclic heptapeptideAnalog of alpha-MSH with an internal lactam bridge
Molecular weightApproximately 1024 daltonsFree base value; salt forms differ
AppearanceWhite to off-white powderUsually supplied as a lyophilized solid
SolubilityFreely soluble in waterPoorly soluble in nonpolar solvents
Typical storage−20 °C, dry, protected from lightRepeated freeze-thaw cycles degrade peptides

Background from the literature

=== Maintaining microbiome === Mouse PGLYRP2 plays a role in maintaining healthy microbiome, as PGLYRP2-deficient mice have significant changes in the composition of their intestinal microbiome, which affect their sensitivity to colitis.

The Rush website, newly redesigned on March 12, 2007, to support the new album, also announced that the band would embark on a tour to begin in the summer. Snakes & Arrows was released on May 1, 2007, in North America, where it debuted at No. 3 on the Billboard 200 with approximately 93,000 units sold in its first week. It peaked at No. 3 in Canada and No. 13 in the UK, selling an estimated 611,000 copies worldwide. Coinciding with the beginning of Atlantic Ocean hurricane season, "Spindrift" was released as the official second radio single on June 1, 2007, while "The Larger Bowl (A Pantoum)" came out as a single on June 25, 2007. "The Larger Bowl" peaked within the top 20 of both the Billboard Mainstream Rock and Mediabase Mainstream charts, but "Spindrift" failed to appear on any commercial chart. The planned intercontinental tour in support of Snakes & Arrows began on June 13, 2007, in Atlanta, coming to a close on October 29, 2007, at Hartwall Arena in Helsinki, Finland. The 2008 portion of the Snakes & Arrows tour began on April 11, 2008, in San Juan, Puerto Rico, at José Miguel Agrelot Coliseum, and concluded on July 24, 2008, in Noblesville, Indiana at the Verizon Wireless Music Center. On April 15, 2008, the band released Snakes & Arrows Live, a double live album documenting the first leg of the tour, recorded at the Ahoy arena in Rotterdam, Netherlands on October 16 and 17, 2007. A DVD and Blu-ray recording of the same concerts was released on November 24, 2008.

=== Disorders of plasma protein metabolism === 273 Disorders of plasma protein metabolism 273.0 Polyclonal hypergammaglobulinemia 273.1 Monoclonal paraproteinemia 273.2 Other paraproteinemias 273.3 Macroglobulinemia Waldenström macroglobulinemia 273.8 Other disorders of plasma protein metabolism Atransferrinemia

A vein () is a blood vessel in the circulatory system of humans and most other animals that carries blood towards the heart. Most veins carry deoxygenated blood from the tissues back to the heart; exceptions are those of the pulmonary and fetal circulations which carry oxygenated blood to the heart. In the systemic circulation, arteries carry oxygenated blood away from the heart, and veins return deoxygenated blood to the heart, in the deep veins. There are three sizes of veins: large, medium, and small. Smaller veins are called venules, the smallest of which are called post-capillary venules – microscopic veins that play a major role in microcirculation. Veins are often closer to the skin than arteries. Veins have less smooth muscle and connective tissue and wider internal diameters than arteries. Because of their thinner walls and wider lumens they are able to expand and hold more blood. This greater capacity gives them the term of capacitance vessels. At any time, nearly 70% of the total volume of blood in the human body is in the veins. In medium and large sized veins the flow of blood is maintained by one-way (unidirectional) venous valves to prevent backflow. In the lower limbs this is also aided by muscle pumps, also known as venous pumps that exert pressure on intramuscular veins when they contract and drive blood back to the heart.

Sources: en.wikipedia.org

Related pages on this site

Reference notes

Deadlift – 400 kg (882 lb) (2005 Pojedynek Gigantów) Keg drop Deadlift – 295–350 kg (650–771 lb) x 6 lifts in 33.89 seconds (2005 World's Strongest Man) Keg drop Squat – 265–340 kg (584–750 lb) x 7 reps in 21.28 seconds (2007 World's Strongest Man - Group 4) Keg drop Squat – 260–360 kg (573–794 lb) x 7 reps in 27.53 seconds (2005 World's Strongest Man) (former world record) Log lift – 172 kg (379 lb) (2005 Met-Rx Grand Prix) Log lift (for reps) – 130 kg (287 lb) x 14 reps (2006 Moscow Grand Prix) Axle press (for reps) – 140 kg (309 lb) x 11 reps (2006 WSMC Poland) (World Record) Apollon wheel press – 166 kg (366 lb) x 4 reps (2004 Arnold Strongman Classic) Viking press – 150 kg (331 lb) x 12 reps (2007 Mohegan Sun Grand Prix) Kettlebell press – 80 kg (176 lb) x 8 reps (2009 Globe's Strongest Man) Atlas Stones – 5 stones weighing 115–155 kg (254–342 lb) on tall platforms in 21.09 seconds (2006 Strongman Super Series Moscow Grand Prix) (World Record) Ding carry – 160 kg (353 lb) for 90 metres (2005 World's Strongest Man) (World Record) Asia Stone / shield carry – 175 kg (386 lb) for 127.4 metres (2002 World's Strongest Man) (World Record) Africa Stone carry – 175 kg (386 lb) for 110 metres (2000 World's Strongest Man - Group 5) (World Record) Block carry – 180 kg (397 lb) for 80 metre course in 41.32 seconds (2002 Europe's Strongest Man) (World Record) Fridge carry (super yoke) – 410 kg (904 lb) for 20 metres in 15.29 seconds (2005 World's Strongest Man) Timber carry – 392 kg (864 lb) (40' ramp) in 22.93 seconds (Raw grip) (2006 Arnold Strongman Classic) Wheelbarrow carry (no straps) – 300 kg (661 lb) (25m course) in 15.50 seconds (2003 IFSA Finland Grand Prix) (World Record) Farmer's walk (no straps) – 150 kg (331 lb) per each hand for 60m course in 19.90 seconds (2006 Strongman Super Series Poland Grand Prix) (World Record) Farmer's walk (no straps) – 137.5 kg (303 lb) per each hand for 70m course in 22.48 seconds (2003 Strongman Super Series Finland Grand Prix) (World Record) Super Yoke – 360 kg (794 lb) for 20 meters in 7.66 seconds (2006 World Strongman Cup Federation, Poland) (World Record) Medicine Ball Toss – 23 kg (51 lb) for 4.88 meters (2004 Arnold Strongman Classic) Power Stairs – (225 kg (496 lb) total of 14 steps) – 40.94 seconds (2008 World's Strongest Man) (World Record) Power Stairs – (230 kg (507 lb) total of 23 shallow steps) – 26.33 seconds (2006 World's Strongest Man) (World Record) Power Stairs – (200 kg (441 lb), 230 kg (507 lb) & 250 kg (551 lb) total of 15 high steps) – 31.22 seconds (2004 Europe's Strongest Man) (World Record) Power Stairs – (225 kg (496 lb), 250 kg (551 lb) & 275 kg (606 lb) total of 15 steps) – 28.56 seconds (2005 Nautilus Grand Prix) (World Record) Tyre Flip – 380 kg (838 lb) Tyre x 8 flips - 20.81 seconds (2004 Holland Champions Trophy) and 400 kg (882 lb) Tyre x 8 flips - 22.87 seconds (2006 Moscow Grand Prix) (former world records) Flip & drag – 400 kg (882 lb) tyre x 4 flips and 300 kg (661 lb) anchor & chain drag for 30 meters – 39.01 seconds (2002 World's Strongest Man) (world record) Conan's wheel (Basque circle) – 360 kg (794 lb) 765° rotation (2006 World Strongman Cup Russia) (World Record) Conan's wheel (Basque circle) – 317.5 kg (700 lb) 1,203° rotation (2003 Strongman Super Series Holland Grand Prix) (World Record) Conan's wheel (Basque circle) – 300 kg (661 lb) 1,440° rotation (2002 World's Strongest Man - Group 5) (former world record) Train pull – 16,000 kg (35,274 lb) for 25 meter course in 30.78 seconds (2003 World's Strongest Man) (World Record) Truck pull – 24,000 kg (52,911 lb) for 20 meter course in 26.05 seconds (2003 IFSA Strongman World Record Breakers) (World Record) Plane pull – 40,000 kg (88,185 lb) for 25 meter course in 36.67 seconds (2008 World's Strongest Man) (World Record) During training: (Self-claims)

== Career == Merker graduated as a physician at the Free University of Berlin in 1956. In 1957, he was employed at the Research Department of Electron Microscopy, which was headed by Willy Schwarz, at the Institute of Anatomy at the Free University of Berlin. He obtained his doctorate (Dr.med.) in 1958 and his Habilitation in 1964, and was appointed as Adjunct Professor (außerplanmäßiger Professor) at the Free University of Berlin in 1968. In 1969, he became director of the Research Department of Electron Microscopy. He held the first chair in anatomy from 1972 to 1998, in succession to Ernst von Herrath. He also served as Dean of the Faculty of Medicine from 1980 to 1981, and was director of the Institute of Anatomy until 1998. He was a visiting scholar for one year at the Weizmann Institute of Science in Israel in 1965, and was subsequently a visiting scholar at universities in England and Sweden. He wrote more than 250 scientific papers. He became Professor Emeritus in 1998, and died in Berlin in 2014.

== History == Hepcidin was initially reported and named in January 1998, after it was observed that it was produced in the liver and appeared to have bactericidal (bacteria-killing) properties. Detailed descriptions were published in 2000–2001. Although it is primarily synthesized in the liver, smaller amounts are synthesized in other tissues such as fat cells. Hepcidin was first discovered in human urine and blood serum. Soon after this discovery, researchers discovered that hepcidin production in mice increases in conditions of iron overload as well as inflammation. Genetically modified mice engineered to overexpress hepcidin died shortly after birth with severe iron deficiency, again suggesting that hepcidin plays a central and not redundant role in iron regulation. The first piece of evidence that linked hepcidin to the clinical condition known as the anemia of inflammation came from the lab of Nancy Andrews in Boston, when researchers looked at tissue from two patients with liver tumors with a severe microcytic anemia that did not respond to iron supplements. The tumor tissue appeared to be overproducing hepcidin, and contained large quantities of hepcidin mRNA. Removing the tumors surgically cured the anemia.

The live video Three of a Perfect Pair: Live in Japan was released later in 1984 on VHS (and later also included on the Neal and Jack and Me DVD). The last concert of the Three of a Perfect Pair tour, at the Spectrum in Montreal on 11 July 1984, was recorded and released in 1998 as Absent Lovers: Live in Montreal. Further live recordings of the 1980s band would be released in 2016 as part of the On (and off) The Road (1981–1984) box set. Despite their conflict, the musicians remained professional on stage.

=== General and cited sources === Benn, James A. (2015). Tea in China: A Religious and Cultural History. Hong Kong University Press. ISBN 978-988-8208-73-9. Heiss, Mary Lou; Heiss, Robert J. (2007). The Story of Tea: A Cultural History and Drinking Guide. Ten Speed Press. ISBN 978-1-58008-745-2. Mair, Victor H.; Hoh, Erling (2009). The True History of Tea. Thames & Hudson. ISBN 978-0-500-25146-1. Martin, Laura C. (2007). Tea: The Drink that Changed the World. Tuttle Publishing. ISBN 978-0-8048-3724-8. OCLC 1159227468. OL 1956186W.

Sources: en.wikipedia.org

Frequently asked questions

What is melanotan-2?

It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.

How does it differ from melanotan-1?

Melanotan-1, also called afamelanotide, is a shorter linear analog with a different amino acid sequence and no lactam ring. It has been evaluated in formal clinical programs, while melanotan-2 has not. The two are distinct molecules and are not interchangeable.

Is it the same as bremelanotide?

No. Bremelanotide is a related but distinct cyclic peptide that reached approved status for one specific clinical indication. Melanotan-2 is a separate molecule with its own sequence and properties. Shared ancestry in the melanocortin family does not make them the same substance.

What class of compound is melanotan-2?

It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.

Network